News & Events

Physiomics launches updated website

Physiomics is pleased to announce that following feedback from clients and shareholders it has today updated its website at http://www.physiomics-plc.com/.  In its recent placing…

Placing

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to watch video.

Contract award

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce…

Physiomics to Present at BioTrinity 2018

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce…

Physiomics to Present at the American Association for Cancer Research (“AACR”) Annual Meeting

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce…

Issue of Options

The Company considers that the award of options linked to company performance are critical to the incentivisation of its senior employees and to ensure that there is alignment between management and shareholders.

Award of New Innovate UK Grant

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that is has been awarded a new grant by Innovate UK, the UK’s innovation agency.

Completion of Innovate UK Grant Project on Personalised Treatment of Oesophageal Cancer

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in January 2017. 

Interim Results Statement for the six-month period ended 31 December 2017

Oxford, UK, 19 February 2018: The Board of Physiomics Plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the…